TG Therapeutics, Inc.

NasdaqCM:TGTX Stok Raporu

Piyasa değeri: US$5.0b

TG Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

TG Therapeutics yıllık ortalama 27.4% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19.3% annual. Gelirler yılda ortalama 86.1% oranında büyüyor .

Anahtar bilgiler

27.4%

Kazanç büyüme oranı

33.3%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı86.1%
Özkaynak getirisi-7.5%
Net Marj-5.4%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Optimistic Investors Push TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Up 27% But Growth Is Lacking

Nov 07
Optimistic Investors Push TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Up 27% But Growth Is Lacking

TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates

Nov 05

TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shares Bounce 27% But Its Business Still Trails The Industry

Sep 01
TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shares Bounce 27% But Its Business Still Trails The Industry

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 09
Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback

Aug 07

TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet

Aug 02
TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet

Hold TG Therapeutics For Intriguing Outcomes

Jun 12

TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement

May 29
TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement

TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 04
TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

TG Therapeutics: Less Room For Doubt About Briumvi

May 03

News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

May 03
News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet

Mar 25
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet

TG Therapeutics: Briumvi Growth Story Appears Intact

Mar 01

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 01
Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference

Jan 10

Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S

Jan 04
Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S

Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?

Nov 24
Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?

TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar

Sep 30
TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar

Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

Aug 03
Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Jul 19
Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?

Apr 13
Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?

Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?

Jan 02
Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?

TG Therapeutics: Elucidating The Upcoming Binary

Oct 09

TG Therapeutics: We Are Just Hanging In There

Sep 21

Gelir ve Gider Dağılımı

TG Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqCM:TGTX Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 24265-1414688
30 Jun 243479613782
31 Mar 242894112993
31 Dec 232341312376
30 Sep 23190-2611488
30 Jun 2324-1769694
31 Mar 239-1697793
31 Dec 223-19870125
30 Sep 225-23980158
30 Jun 227-288101190
31 Mar 228-326122208
31 Dec 217-348128223
30 Sep 214-343140203
30 Jun 212-345140201
31 Mar 211-319120193
31 Dec 200-279108166
30 Sep 200-23171154
30 Jun 200-20639161
31 Mar 200-18927158
31 Dec 190-17315154
30 Sep 190-18710176
30 Jun 190-1598151
31 Mar 190-16711157
31 Dec 180-17315159
30 Sep 180-15018133
30 Jun 180-14822127
31 Mar 180-13218115
31 Dec 170-11816103
30 Sep 170-1111399
30 Jun 170-1051293
31 Mar 170-921280
31 Dec 160-781069
30 Sep 160-721162
30 Jun 160-611052
31 Mar 160-621350
31 Dec 150-631648
30 Sep 150-641748
30 Jun 150-681850
31 Mar 150-631845
31 Dec 140-561640
30 Sep 140-431429
30 Jun 140-301118
31 Mar 140-24817
31 Dec 130-20714

Kaliteli Kazançlar: TGTX şu anda kârlı değil.

Büyüyen Kar Marjı: TGTX şu anda kârlı değil.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: TGTX kârlı değildir, ancak son 5 yılda zararlarını yılda 27.4% oranında azaltmıştır.

Büyüme Hızlandırma: TGTX 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: TGTX kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.


Özkaynak Getirisi

Yüksek ROE: TGTX hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -7.48% ) sahiptir.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin